Newstral
Biocon
- Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn), Biosimilar to Stelara® Approved by FDAjdsupra.com
- Sensex up 250 points near 73,900; Nifty50 above 22,400The Times of India
- EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed for Lack of Jurisdictionjdsupra.com
- Sensex dips over 200 points, Nifty50 slips below 22,100The Times of India
- EYLEA® IPR Appeals Filedjdsupra.com
- Stelara® Biosimilar Updates: Settlement of IPR and FDA Review of Proposed Biosimilarjdsupra.com
- PTAB Institutes Celltrion and Biocon IPRs on Regeneron Aflibercept Dosing Patentjdsupra.com
- Breaking: Judgment in Regeneron v. Mylan (aflibercept) BPCIA Case Finding Some Claims of Asserted Patents Valid and Infringedjdsupra.com
- Sitharaman in forbes' most powerful women listThe Times of India
- Update: Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Case Now Completejdsupra.com
- Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Casejdsupra.com
- One of Scotland's richest men dies aged 73 as wife pays tribute to 'mentor and soul mate'The Daily Record
- U.S. Prescription Drug Market Lacks Certain Competitive Features: Case Of BiosimilarsForbes
- HCL heiress Roshni richest woman with Rs 84,000 croreThe Times of India
- Traffic, infrastructure woes get worse in BengaluruThe Times of India
- GErythropoietin (EPO) Drugs Market, Global Outlook and Forecast 2022-2028galleonnews.com
- GTargeted Drug VEGF Inhibitors for NSCLC Market – Global Outlook and Forecast 2022-2028galleonnews.com
- Can the BJP’s strategy succeed in Karnataka?The Hindu
- Brace for hot, dry April in north, warns IMDThe Times of India
- BJP slams Biocon chief’s ‘communal exclusion’ warningThe Times of India
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.